Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|December 17, 2021
ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell FunctionSilvia D'Amico, Valerio D'Alicandro, Mirco Compagnone, et al.
International Journal of Molecular Sciences|February 26, 2025
Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot TumorsValeria Lucarini, Ombretta Melaiu, Paula Gragera, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 5, 2016
A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid CarcinomaGisella Figlioli, Rossella Elisei, Cristina Romei, et al.
Plos One|January 28, 2014
MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesotheliomaOmbretta Melaiu, Justin Stebbing, Ylenia Lombardo, et al.
Nature Communications|November 26, 2020
Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastomaOmbretta Melaiu, Marco Chierici, Valeria Lucarini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in NeuroblastomaOmbretta Melaiu, Marco Mina, Marco Chierici, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy peopleSonia Garritano, Chiara De Santi, Roberto Silvestri, et al.
Thyroid : Official Journal of the American Thyroid Association|April 2, 2020
Polymorphisms Within the RET Proto-Oncogene and Risk of Sporadic Medullary Thyroid CarcinomaFederica Gemignani, Cristina Romei, Raffaele Ciampi, et al.
Cancer Treatment Reviews|October 23, 2024
Crosstalk and communication of cancer-associated fibroblasts with natural killer and dendritic cells: New frontiers and unveiled opportunities for cancer immunotherapySimone Ielpo, Francesca Barberini, Farnaz Dabbagh Moghaddam, et al.
Investigational New Drugs|December 10, 2020
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesotheliomaIrene Dell'Anno, Sarah A Martin, Marcella Barbarino, et al.
Pageof 7